ReWalk Exoskeleton Shows Long-Term Home Use Viability in New Study

  • ReWalk Personal Exoskeleton used for a median of 33 months in a peer-reviewed study, with no reported falls or fractures.
  • Participants averaged over 3,000 steps per month, demonstrating sustained real-world utilization.
  • High user satisfaction reported, with median QUEST satisfaction score of 4.2 out of 5.
  • Study published in Spinal Cord Series and Cases, an official journal of the International Spinal Cord Society.

The study provides critical long-term evidence for ReWalk's safety and efficacy, addressing a gap in existing literature focused on shorter-term, controlled settings. This data could bolster Lifeward's efforts to expand access and reimbursement, positioning ReWalk as a sustainable solution for chronic paraplegia management. The findings also underscore the importance of caregiver availability, a factor that could influence future product design and support services.

Reimbursement Expansion
Whether the long-term evidence will accelerate Medicare and private payer coverage for ReWalk.
Market Adoption
The pace at which clinical and real-world evidence translates into broader adoption by patients with chronic paraplegia.
Competitive Positioning
How Lifeward leverages this data to differentiate ReWalk in the growing exoskeleton market.